Gliclazid tablets 80 mg. №30


Manufacturer: Ukraine

Type II diabetes in adults reducing and controlling blood glucose when it is not possible to normalize glucose levels only by diet, exercise, and weight loss prevention of complications of type II diabetes: reducing the risk of macro-and microvascular complications, including new cases or worsening of nephropathy in patients with type II diabetes who are treated with an intensive glycemic control strategy.



Gliclazid №30 Composition
Dosage form

Basic physical and chemical properties: flat-cylindrical white tablets with a line.

Gliclazid №30 Pharmacotherapeutic group
Antidiabetic drugs. Sulfonamides, sulfonylurea derivatives. ATX code А10В В09.

Gliclazide is a sulfonylurea derivative and belongs to synthetic oral hypoglycemic drugs of the second generation. The drug restores the early peak of insulin secretion, affects the transport of calcium in the b-cells of the pancreas. The peculiarity of the chemical structure of second-generation drugs leads to their greater affinity for the sulfonylurea receptor on the b-cell membrane. This action is realized according to the following mechanism: a decrease in the permeability of the membrane of b-cells to potassium ions ® depolarization of the membrane ® entry of calcium ions through channels, the opening of which depends on changes in the electrical potential of the membrane ® increase in the concentration of intracellular calcium ® release of insulin from cytoplasmic granules.

After oral administration, it is rapidly and completely absorbed from the digestive tract. Bioavailability is about 90%. Cmax in the blood is reached in 11-14 hours. Plasma protein binding is 94.2%. It is metabolized in the liver by oxidation, hydroxylation, glucuronidation to form 8 inactive metabolites. T½ is 20 hours, which allows you to take the drug 2 times a day. It is excreted in the form of metabolites, mainly by the kidneys.

Diabetes mellitus type II (non-insulin dependent) in adults, if it is impossible to control the concentration of glucose in the blood only by diet, exercise or weight loss.

Gliclazid №30 Contraindications

Hypersensitivity to gliclazide or other sulfonylurea drugs;
hypersensitivity to sulfonamides or to any component of the drug;
insulin-dependent diabetes;
severe hepatic or renal impairment, in such cases insulin administration is recommended;
diabetic ketoacidosis;
diabetic coma and coma;
severe injuries, burns or infectious diseases in the acute period;
simultaneous treatment with miconazole;
simultaneous treatment with quinolone;
During pregnancy and breastfeeding.